Drug Eluting Balloons - Market Insights, Competitive Landscape, and Market Forecast - 2028
상품코드:1397170
리서치사:DelveInsight
발행일:2023년 12월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 약물 용출 풍선 시장 규모는 2023년부터 2028년까지 예측 기간 동안 8.31%의 CAGR로 확대될 것으로 예상됩니다. 약물 용출 풍선에 대한 수요는 주로 말초 동맥 질환 및 관상동맥 질환을 포함한 여러 심장 질환의 유병률 증가에 의해 주도되고 있습니다. 또한, 최소 침습적 치료에 대한 선호도 증가, 약물 용출 스텐트 대비 풍선 카테터의 우월성, 노인 인구의 증가 등이 향후 몇 년 동안 약물 용출 풍선에 대한 수요를 증가시킬 것으로 예상됩니다. 또한, 신흥국을 중심으로 한 의료비 지출 증가, 제품 출시 및 승인 증가, 주요 기업의 연구개발 활동 급증 등이 2023-2028년 예측 기간 동안 전체 약물 용출 풍선 시장의 성장에 기여하고 있습니다.
약물 용출 풍선 시장은 다양한 요인으로 인해 제품 수요가 증가하고 있으며, 주요 요인 중 하나는 말초 동맥 질환과 관상동맥 질환을 포함한 심장 질환의 수치가 상승하고 있다는 점입니다.
예를 들어, 미국심장협회(American Heart Association)에 따르면, 2020년에는 전 세계적으로 2억 4,410만 명이 관상동맥질환으로 알려진 허혈성 심장질환(IHD)을 앓고 있는 것으로 추정됩니다. 같은 자료에 따르면, 여성보다 남성이 더 많은데, 각각 1억 4,100만 명과 1억 310만 명으로 나타났습니다.
또한 British Heart Foundation 2023은 2019년 말초동맥(혈관) 질환이 전 세계적으로 1억 1,000만 건을 차지할 것으로 추정하고 있습니다.
이러한 관상동맥 및 말초 동맥 질환의 유병률 증가는 질병의 치료 및 관리에 자주 사용되기 때문에 약물 용출 풍선에 대한 수요를 증가시킬 것입니다.
또한, 이러한 카테터는 약물 용출 스텐트에 비해 표적 약물전달에 있어 다양한 장점이 있어 많은 심혈관 적응증에 대한 혈관성형술에서 사용이 증가하고 있습니다. 이러한 장치는 스텐트 및 개복 수술에 비해 더 나은 혈관 조영술 및 임상 결과를 제공합니다. 또한, 약물 코팅 풍선은 최소한의 부작용을 포함한 다양한 장점으로 인해 관상동맥 질환에 대한 가장 적응성이 높은 치료 접근법입니다. 또한, 약물 코팅 풍선 카테터를 이용한 최소침습적 수술은 위험도가 높은 스텐트 치료의 대안으로 심근경색 치료법으로 주목받고 있습니다.
또한, 시장 진입 기업들은 인지도를 높이기 위해 자주 신제품을 개발하고 있습니다. 예를 들어, 2023년 6월, 의료기기 및 체외 진단 기술을 헬스케어 산업에 제공하는 선도적인 업체인 서모딕스(Surmodics, Inc.)는 SurVeil(TM) 약물 코팅 풍선(DCB)에 대한 미국 식품의약국(FDA)의 승인을 획득했습니다.
따라서 위의 요인들은 2023년부터 2028년까지의 예측 기간 동안 약물 용출 풍선 시장의 성장에 기여하고 있습니다.
그러나 부작용, 제품 회수, 엄격한 규제 절차 등은 약물 용출 풍선 시장의 성장을 제한할 수 있습니다.
이 보고서는 세계 약물 용출 풍선 시장을 조사하여 시장 개요와 함께 제품 유형별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 제공합니다.
목차
제1장 약물 용출 풍선 시장 보고서 서론
제2장 약물 용출 풍선 시장 주요 요약
제3장 규제 분석
미국
유럽
일본
중국
제4장 약물 용출 풍선 시장의 주요 요인 분석
약물 용출 풍선 시장 촉진요인
약물 용출 풍선 시장 억제요인과 과제
약물 용출 풍선 시장 기회
제5장 약물 용출 풍선 시장의 Porter's Five Forces 분석
제6장 약물 용출 풍선 시장 개요
제품 유형별
최종사용자별
지역별
제7장 약물 용출 풍선 시장의 기업과 제품 프로파일
Boston Scientific Corporation
BD
Terumo Corporation
Medtronic
Koninklijke Philips N.V.
Cordis
Cook
BIOTRONIK
SurModics Inc.
B. Braun SE
Aachen Resonance Entwicklungsgesellschaft mbH
Biosensors International Group, Ltd.
Eurocor GmbH
iVascular
Innvolution
Cardiovascular Systems, Inc.
Genesis Medtech
Concept Medical
Cardionovum GmbH
YINYI(LIAONING) BIOTECH CO., LTD.
제8장 KOL의 견해
제9장 프로젝트 접근법
제10장 DelveInsight 소개
제11장 면책사항과 문의
ksm
영문 목차
영문목차
Drug-Eluting Balloon Market By Product Type (Coronary Drug-Eluting Balloon, Peripheral Drug-Eluting Balloon, And Others), End-User (Hospitals, Ambulatory Surgical Centers, And Others), and geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of peripheral and coronary artery diseases and rising demand for minimally invasive procedures across the globe.
Global drug-eluting balloon market is estimated to grow at a CAGR of 8.31% during the forecast period from 2023 to 2028. The demand for drug-eluting balloons is primarily being boosted by the increasing prevalence of numerous heart diseases including peripheral and coronary artery diseases. Furthermore, the increasing preference for minimally invasive procedures, the advantages of balloon catheters over drug-eluting stents, the rising elderly population base, and others will propel the demand for drug-eluting balloons in the upcoming years. In addition, growing healthcare spending, especially in emerging countries, rising product launches and approvals, and surging research and developmental activities by the key players, among others are thereby contributing to the overall growth of the drug-eluting balloon market during the forecast period from 2023-2028.
Drug-Eluting Balloon Market Dynamics:
The drug-eluting balloon market is witnessing a growth in product demand owing to various factors, one of the key factors being the rising figures of heart diseases comprising peripheral and coronary artery disease.
For instance, according to the American Heart Association 2022, globally, it was estimated that in 2020, 244.1 million people were living with ischemic heart disease (IHD), also known as coronary heart or coronary artery disease. The same source estimated that it was more prevalent in males than in females, 141.0 and 103.1 million people, respectively.
Further, British Heart Foundation 2023 estimated that the peripheral arterial (vascular) disease accounted for 110 million cases in 2019, globally.
Thus, the increasing prevalence of coronary and peripheral artery disease will increase the demand for drug-eluting balloons as they are frequently used to treat and manage the disease.
Additionally, various advantages of these catheters over drug-eluting stents in targeted drug delivery have increased their use in angioplasty surgeries for a number of cardiovascular indications. These devices provide better angiographic and clinical outcomes as compared to stents or open surgeries. Also, the drug-coated balloons are the most adaptive therapeutics approach for coronary disease due to their various advantages including minimal side effects. Further, drug-coated balloon catheter usage with minimally invasive procedures is a preferable replacement over risky stent treatment for myocardial infarction.
Also, market participants frequently develop new products to increase their visibility. For instance, in June 2023, Surmodics, Inc., a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, received the US Food and Drug Administration (FDA) approval for the SurVeil™ drug-coated balloon (DCB).
Therefore, the above-mentioned factors are contributing to the growth of the drug-eluting balloon market during the forecast period from 2023-2028.
However, adverse effects and product recalls, stringent regulatory procedures and others may restrict the drug-eluting balloon market growth.
Drug-Eluting Balloon Market Segment Analysis:
Drug-eluting Balloon Market by Product Type (Coronary Drug-Eluting Balloon, Peripheral Drug-Eluting Balloon, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World).
In the product type segment of the drug-eluting balloon market, the peripheral drug-eluting balloon category is expected to amass a significant revenue share in the year 2022. This was primarily owing to the benefits that various the segment and the rising figures of peripheral artery disease (PAD) across the globe.
According to DelveInsight estimates, the US accounted for approximately 9 million cases, which was the highest diagnosed prevalent cases of peripheral artery disease, followed by EU4 and the UK with 5 million cases, and Japan with 2 million cases in 2022. Further, among the European countries, Germany had the highest diagnosed prevalent population of peripheral artery disease (approximately 2 million cases), followed by Italy (approximately 1 million cases) in 2022. On the other hand, Spain (0.7 million cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.
Thus, the above statistics show that PAD is increasing at a faster pace, which is ultimately driving the segment for peripheral drug-eluting balloons.
Numerous businesses and key players in this field are also working to create technologically advanced peripheral drug-eluting balloons. For instance, in August 2022, BD (Becton, Dickinson, and Company), a leading global medical technology company, announced the start of enrollment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB). The PREVISION trial is a prospective, multicenter, single-arm, non-randomized study designed to evaluate the safety of the BD sirolimus DCB in the treatment of peripheral arterial disease in the femoropopliteal arteries.
Also, in November 2020, Boston Scientific received US Food and Drug Administration (FDA) approval for the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Thus, the above-mentioned factors are likely to propel the demand for peripheral drug-eluting balloons, thereby contributing to the growth of the drug-eluting balloon market during the forecast period from 2023-2028.
North America is expected to dominate the overall Drug-Eluting Balloon Market:
Among all the regions, North America is estimated to account for the largest share in the drug-eluting balloon market in the year 2022. This domination is due to the increasing application of drug-eluting balloons in the treatment and management of peripheral and coronary artery disease, increasing sedentary lifestyle lacking physical activity, lack of proper diet, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases, rising product launch and approvals, presence of favorable regulatory authority, among others will propel the market of drug-eluting balloon in North America.
For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) in 2023, it was stated that in 2021, about 1 in 20 adults age 20 and older have coronary artery disease (CAD). Coronary heart disease is the most common type of heart disease in the US, killing 375,476 people in 2021. In 2021, about 2 in 10 deaths from CAD happen in adults less than 65 years old. Thus, the high burden of cardiovascular diseases in the region demands the availability of drug-eluting balloons.
The American Heart Association in the latest study estimated that over 500,000 percutaneous coronary intervention (PCI) procedures are carried out annually in the US. Percutaneous coronary intervention with a drug-coated balloon (DCB) is a novel treatment that seeks to acutely dilate coronary stenosis and deliver an anti-proliferative drug to the vessel wall. Thus, the surging number of PCI procedures in the region will increase the demand for drug-eluting balloons.
Further, the availability of various major manufacturers, the launch and approval of new and technologically advanced devices, and favorable reimbursement regulations are all important factors responsible for driving the demand for drug-eluting balloons in the region. For instance, in November 2022, Genesis MedTech Group announced that the Food and Drug Administration (FDA) has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery.
Thus, all the above-mentioned factors will lead to an increase in the North America drug-eluting balloon market growth during the forecasting period of 2023-2028.
Drug-Eluting Balloon Market Key Players:
Some of the key market players operating in the drug-eluting balloon market include: Boston Scientific Corporation, BD, Terumo Corporation, Medtronic, Koninklijke Philips N.V., M.A. Med Alliance SA., Cook, BIOTRONIK, SurModics Inc., B. Braun SE, Aachen Resonance Entwicklungsgesellschaft mbH, Biosensors International Group, Ltd., Eurocor GmbH, iVascular, Innvolution, Cardiovascular Systems, Inc., Genesis Medtech, Concept Medical, Cardionovum GmbH, YINYI (LIAONING) BIOTECH CO., LTD., and others.
Recent Developmental Activities in the Drug-Eluting Balloon Market:
In May 2023, the US FDA granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.
In September 2022, the FDA granted Advanced NanoTherapies a Breakthrough Device Designation (BDD) for its SirPlux Duo Drug-Coated Balloon (DCB) to treat coronary artery disease.
In October 2022, Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance, a Switzerland-based company at the forefront of transformative drug-eluting balloons.
In February 2021, Cardiovascular Systems, Inc. partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI's leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer in the successful development of several drug-coated devices.
Key Takeaways from the Drug-Eluting Balloon Market Report Study:
Market size analysis for current drug-eluting balloon market size (2022), and market forecast for 5 years (2023-2028)
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global drug-eluting balloon market.
Various opportunities available for the other competitor in the drug-eluting balloon market space.
What are the top-performing segments in 2022? How these segments will perform in 2028.
Which are the top-performing regions and countries in the current drug-eluting balloon market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for drug-eluting balloon market growth in the coming future?
Target Audience who can be benefited from this Drug-Eluting Balloon Market Report Study:
Drug-eluting balloon products providers
Research organizations and consulting companies
Drug-eluting balloon-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in a drug-eluting balloon
Various End-users who want to know more about the drug-eluting balloon market and the latest technological developments in the drug-eluting balloon market.
Frequently Asked Questions for the Drug-Eluting Balloon Market:
1. What is a drug-eluting balloon?
Drug-eluting balloons also known as drug-eluted balloon catheters are semi-compliant angioplasty balloons that are used to elute the drug in the targeted vessel.
2. What is the market for global drug-eluting balloons?
Global drug-eluting balloon market is estimated to grow at a CAGR of 8.31% during the forecast period from 2023 to 2028.
3. What are the drivers for the global drug-eluting balloon market?
The demand for drug-eluting balloons is primarily being heightened by the rise in the number of patients suffering from atherosclerosis, obstructive coronary artery disease, peripheral vascular disease, and others. Additionally, technological improvements in the devices, rising the demand for minimally invasive surgical treatments, the increasing elderly population base, and surging market players' concentration on creating cost-efficient, accurate, and effective drug-eluting balloon catheters among others are thereby contribute to the overall growth of the drug-eluting balloon market during the forecast period from 2023-2028.
4. Who are the key players operating in the global drug-eluting balloon market?
Some of the key market players operating in the drug-eluting balloon market include Boston Scientific Corporation, BD, Terumo Corporation, Medtronic, Koninklijke Philips N.V., Cordis, Cook, BIOTRONIK, SurModics Inc., B. Braun SE, Aachen Resonance Entwicklungsgesellschaft mbH, Biosensors International Group, Ltd., Eurocor GmbH, iVascular, Innvolution, Cardiovascular Systems, Inc., Genesis Medtech, Concept Medical, Cardionovum GmbH, YINYI (LIAONING) BIOTECH CO., LTD., and others.
5. Which region has the highest share in the drug-eluting balloon market?
North America is expected to dominate the overall drug-eluting balloon market during the forecast period from 2023-2028. Factors such as the increasing prevalence of peripheral and coronary artery disease, rising geriatric population base in the region, surging demand for minimally invasive surgeries, availability of various major manufacturers in the region, increasing launches and approvals of new and technologically advanced devices, and favorable reimbursement regulations among others will positively impact the North American drug-eluting balloon market.
